Interim report - Q1 2014/15: Strong and stable earnings –

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Interim report - Q1 2014/15: Strong and stable earnings – solid market position retained

Q1 2014/15 revenue grew 3.0% year on year to DKK 827 million. Like-for-like growth was 1.4% in Q1 2014/15, including a minor negative calendar effect. EBITA was DKK 130 million in Q1 2014/15 equivalent to an EBITA margin of 15.8%, down from 16.9% in the year-earlier period. The guidance for earnings and the financial targets for the full year are retained although the growth rate fell slightly short of expectations.

Terje List, Chief Executive Officer, said: "We have noted that the Danish retail market remains difficult, contributing to dampening revenue growth, which, at the rate of 3% in Q1, was slightly below our expectations. However, thanks to our robust business model, we again successfully retained our position in the market, which we expect will benefit us in the remaining part of the year."

 

  • Q1 2014/15 revenue grew 3.0% year on year to DKK 827 million. Like-for-like growth was 1.4% and was adversely affected by fewer business days this year than in Q1 2013/14. The consolidation of acquired operations accounted for 1.6% of the revenue growth in Q1 2014/15.
  • Q1 gross profit was DKK 386 million, equivalent to a gross margin of 46.7%, up from 46.6% in Q1 2013/14.
  • EBITA was DKK 130 million in Q1 2014/15 equivalent to an EBITA margin of 15.8%, down from 16.9% in the year-earlier period.
  • Profit after tax for the period was DKK 68 million, and adjusted profit after tax net of amortisation of trademarks was DKK 82 million (Q1 2013/14: DKK 82 million).
  • Cash generated from operations increased to DKK 184 million in Q1 2014/15 (Q1 2013/14: DKK 46 million). The free cash flow was an inflow of DKK 156 million (Q1 2013/14: an inflow of DKK 3 million).
  • Net interest bearing debt was DKK 1,468 million at 30 June 2014, equivalent to 2.4x LTM adjusted EBITDA before exceptional items as compared to 2.9x at the end of Q1 2013/14.
  • At the Annual General Meeting held on 30 June 2014, a resolution was passed to declare a dividend of 5.50 per share of DKK 2.50, equivalent to a total dividend of DKK 224 million, which will be recognised in the cash flow statement for Q2 2014/15.
  • Club Matas continued the net membership growth in Q1, retaining its position as the largest customer club in Denmark.

    

Outlook for 2014/15 The financial targets for the Group for 2014/15 are unchanged as follows:

  • Revenue is expected to be around DKK 3.5 billion, assuming like-for-like growth of 2-3% after taking into account a negative calendar effect.
  • The EBITA margin is expected to be on a level with the 2013/14 EBITA margin, which was 17.1%.

The Danish retail market was challenging in the first quarter of the financial year with continuing weak demand among consumers despite an improvement in consumer confidence. The financial targets for 2014/15 are based on an assumption of unchanged market conditions in the near term but an increase in consumption towards the end of the financial year. Moreover, it is expected that the Group will be in a position to continue to grow its market share.

  

Conference call Matas will host a conference call for investors and analysts on Thursday, 21 August at 11:00 a.m. The conference call and presentation will be available on our investor website: investor.en.matas.dk. 

Conference call access numbers for investors and analysts:  

DK +45 32 72 80 18
UK / International +44 (0) 1452 555 131
US +1 866 682 8490

 

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 49

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 273

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 79

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
HONGQI's EHS4 Launch in Europe: Bridging East and West

Updated Category News Views 290

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 133

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 189

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 103

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 21

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 675

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 188

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring AI's Impact on CRM Visibility and Brand Trust

Updated Category News Views 217

Understanding the Role of AI in CRM Visibility Brandi AI has recently launched its AI Visibility Index series, which offers insightful measurements of how industries are perceived in AI-generated responses. This new series highlights the ways in which customer relationship management (CRM) brands are represented through the lens of advanced AI answer engines. The AI...

Continue Reading
Celldex Therapeutics Thrives Amid Developments with Briquilimab

Updated Category News Views 148

Overview of Celldex Therapeutics and Briquilimab Celldex Therapeutics (NASDAQ: CLDX) is navigating an exciting phase as it explores treatments for chronic conditions like Chronic Inducible Urticaria (CIndU). Analysts have closely observed the efficacy of briquilimab, highlighting its performance through recent studies. Analyst Insights on Celldex and Briquilimab Goldman...

Continue Reading
XPENG's Financial Success in Q3 2024: Key Insights Revealed

Updated Category News Views 238

XPENG's Journey in the Third Quarter of 2024 XPeng Inc. (“XPENG” or “the Company,” NYSE: XPEV and HKEX: 9868) recently disclosed its financial results for the third quarter ended September 30, 2024. This marks a significant period showcasing growth in revenues and vehicle deliveries, reflecting the company's robust strategy in the smart electric vehicle market....

Continue Reading
Apple Inc. Beats Earnings Expectations: Analysts React

Updated Category News Views 144

Apple Inc. Overcomes Challenges with Strong Quarterly Results Apple Inc.‘s latest quarterly performance has generated significant buzz in the tech world. Analysts reveal that the results showcase a resilient company navigating through various market challenges. This performance not only reflects strong sales of products like the iPhone but also highlights impressive...

Continue Reading
Class Action Alert: Investors Have Rights with AMMO, Inc.

Updated Category News Views 237

Class Action Lawsuit Against AMMO, Inc. In a proactive move for investors, Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against AMMO, Inc. (NASDAQ: POWW). This suit comes in light of significant losses experienced by investors in the company due to alleged misstatements and omissions regarding its business practices. Understanding the Class...

Continue Reading